Stock Taper
Neonc Technologies Holdings, Inc., founded in 2023 in Los Angeles, develops innovative molecular therapies like NEO100 and NEO212 for CNS diseases, with NEO100 in Phase 2a trials for glioblastoma.

NEO100, Neonc's lead intranasal drug for CNS cancers like glioblastoma, is a purified perillyl alcohol in Phase 2a trials, aiming to bypass the blood-brain barrier and advance treatment options.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
IVVD | $2.40 | COMPARE |
OBIO | $4.57 | COMPARE |
IVA | $4.49 | COMPARE |
OABI | $2.17 | COMPARE |
TARA | $6.00 | COMPARE |
SLS | $2.00 | COMPARE |
MDWD | $19.29 | COMPARE |
CDXS | $1.70 | COMPARE |